SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-297092
Filing Date
2020-11-18
Accepted
2020-11-18 17:18:02
Documents
13
Period of Report
2020-11-12
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d89335d8k.htm   iXBRL 8-K 28450
2 EX-2.1 d89335dex21.htm EX-2.1 636930
  Complete submission text file 0001193125-20-297092.txt   937954

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rtrx-20201112.xsd EX-101.SCH 3094
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rtrx-20201112_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rtrx-20201112_pre.xml EX-101.PRE 11424
6 EXTRACTED XBRL INSTANCE DOCUMENT d89335d8k_htm.xml XML 3368
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 201326008
SIC: 2834 Pharmaceutical Preparations